N-acetylation phenotype in bladder cancer

1 N-acetylation phenotype has been examined in 30 patients with bladder cancer and in 27 controls of similar age. 2 59% of controls and 70% of bladder cancer patients were phenotypically 'slow' acetylators. This difference was not significant (P greater than 0.30). 3 Within phenotypes, isoniazed half life was similar in controls and bladder cancer patients. 4 N-acetylation phenotype is unlikely to be a major determinant in the pathogenesis of bladder cancer in the population studied.